UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Low dose hyper-radiosensitivity in metastatic tumors

Harney, J; Short, S; Shah, N; Joiner, M; Saunders, MI; (2004) Low dose hyper-radiosensitivity in metastatic tumors. International Journal of Radiation Oncology Biology Physics , 59 (4) pp. 1190-1195. 10.1016/j.ijrobp.2003.12.029.

Full text not available from this repository.

Abstract

Introduction: The laboratory phenomenon of low dose hyper- radiosensitivity (LDHRS) describes excess cell kill at doses below 1 Gy relative to that predicted by the linear quadratic model. These data have stimulated the investigation of whether LDHRS can be exploited clinically. Methods: Patients with metastatic tumor nodules to skin were recruited. The nodules were measured in three dimensions, consecutively numbered according to volume, and randomized, in matched pairs, to receive either conventionally fractionated radiotherapy (1.5 Gy/day) or ultrafractionated radiotherapy (0.5 Gy TDS: 4-h gap). Both groups were treated for 12 days. Measurements were taken Days 0, 5, 8, 12, and 26 and monthly until regrowth occurred. Tumor volumes were normalized to those on Day 0 and plotted against time from the start of treatment.. Time to regrowth to original volume was calculated and compared between groups using the Wilcoxon signed rank test. Results: Eight patients with a total of 40 paired nodules were analyzed; 36 nodules have regrown and are therefore evaluable. Analysis of the whole data set demonstrates a two-tailed p-value of 0.14 in favor of the "ultrafractionated" treatment. Analysis of the tumors generally accepted as being radioresistant and known to show LDHRS in vitro demonstrates a two-tailed p value of 0.009. Conclusions: LDHRS can be demonstrated in tumors clinically. An "ultrafractionated" radiotherapy regime produces significantly increased growth delay in radioresistant malignant tumors. (C) 2004 Elsevier Inc

Type: Article
Title: Low dose hyper-radiosensitivity in metastatic tumors
DOI: 10.1016/j.ijrobp.2003.12.029
Additional information: WoS ID: 000222541300032 JournalEnglishArticle45ELSEVIER SCIENCE INCBEAUCHESNE PD, 2003, INT J CANCER, V105, P33; BRIZEL DM, 1997, INT J RADIAT ONCOL, V38, P285; BRURBERG KG, 2003, BRIT J CANCER, V89, P350; DEACON J, 1984, RADIOTHER ONCOL, V2, P317; DENEKAMP J, 1998, INT J RADIAT ONCOL, V42, P705; DORNER D, 2002, RADIOTHERAPY ONCO S1, V64, PS57; FOWLER JF, 1989, BRIT J RADIOL, V62, P679; GATENBY RA, 1988, INT J RADIAT ONCOL, V14, P831; HAMILTON CS, 1996, RADIOTHER ONCOL, V40, P23; HARNEY J, 2003, INT J RAD ONCOL BI S, V55, P516; HILDEBRANDT G, 1998, INT J RADIAT BIOL, V74, P367; HOCKEL M, 1999, CANCER RES, V59, P4525; HUANG S, 1996, CLIN CANCER RES, V12, P1969; HUANG SY, 1999, J INTERF CYTOK RES, V19, P697; JOINER MC, 1986, INT J RADIAT BIOL, V49, P565; JOINER MC, 2001, INT J RADIAT ONCOL, V49, P379; JOINER MC, 1988, RADIAT RES, V114, P385; JOINER MC, 1993, RECENT RES CANCER, V130, P27; KERN P, 1999, INT J RADIAT BIOL, V75, P995; KRAUSE M, 2003, INT J RADIAT BIOL, V79, P377; LAMBIN P, 1996, INT J RADIAT BIOL, V69, P279; LEITH JT, 1991, INT J RADIAT ONCOL, V20, P203; MARPLES B, 1997, INT J RADIAT BIOL, V71, P721; MARPLES B, 1994, RADIAT RES, V138, PS17; MOULDER JE, 1984, INT J RADIAT ONCOL, V10, P695; NORDSMARK M, 2001, BRIT J CANCER, V84, P1070; NORDSMARK M, 1996, INT J RADIAT ONCOL, V35, P701; NORDSMARK M, 1996, RADIOTHER ONCOL, V41, P31; PARKINS CS, 1986, BR J CANC S, V7, P320; SCHAUE D, 2002, INT J RADIAT BIOL, V78, P567; SHORT S, 1999, INT J RADIAT BIOL, V75, P847; SHORT S, 1999, NEW METHODS OVERCOME; SHORT SC, 2001, INT J RADIAT BIOL, V77, P655; SHORT SC, 1999, INT J RADIAT BIOL, V75, P1341; TAGHIAN A, 1995, INT J RADIAT ONCOL, V32, P99; TAGHIAN A, 1993, INT J RADIAT ONCOL, V25, P243; TAGHIAN A, 1992, INT J RADIAT ONCOL, V23, P55; THAMES HD, 1994, INT J RADIAT BIOL, V56, P457; TROTT KR, 1999, RADIOTHER ONCOL, V51, P197; TROTT KR, 1994, STRAHLENTHER ONKOL, V170, P1; TZAPHLIDOU M, 1997, INT J RADIAT BIOL, V71, P109; VOLL RE, 1997, NATURE, V390, P350; WONG CS, 1992, RADIOTHER ONCOL, V23, P176; WOUTERS BG, 1997, RADIAT RES, V148, P435; WOUTERS BG, 1996, RADIAT RES, V146, P3990JUL 15836FONEW YORKHarney J Mt Vernon Hosp, Marie Curie Res Wing, Northwood HA6 2RN, Middx, EnglandINT J RADIAT ONCOL BIOL PHYS360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
Keywords: CANCER, fractionation, GLIOBLASTOMA-MULTIFORME, GROWTH, HUMAN-MALIGNANT GLIOMA, HYPERSENSITIVITY, IN-VITRO, INCREASED RADIORESISTANCE, INTRINSIC RADIATION SENSITIVITY, LINEAR-QUADRATIC MODEL, low dose hyper, metastases, MOUSE SKIN, radioresistance, radiosensitivity, radiotherapy, SOFT-TISSUE SARCOMAS, SQUAMOUS-CELL CARCINOMA, TUMOR, TUMORS, ultrafractionation, VITRO, VOLUME
UCL classification: UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology
URI: http://discovery.ucl.ac.uk/id/eprint/7085
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item